Cavernous hemangioma of colon

Summary

Cavernous hemangioma of colon (MONDO:0003644) is a disease. A subtype of benign colon neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	cavernous hemangioma of colon
Mondo ID	MONDO:0003644
DOID	DOID:5775
NCIT	C5395
UMLS	C1333086
MedGen	232084
GARD	0023599
Anatomy (UBERON)	UBERON:0001155
Is cancer (heuristic)	no

Also known as: cavernous angioma of colon · cavernous angioma of the colon · cavernous hemangioma of colon · cavernous hemangioma of the colon · colon cavernous angioma · colon cavernous hemangioma · colonic cavernous angioma · colonic cavernous hemangioma

Disease family

This is a subtype of benign colon neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › large intestine disorder › colonic disorder › colonic neoplasm › benign colon neoplasm › cavernous hemangioma of colon

Related subtypes (4): lipoma of colon, colon leiomyoma, colonic lymphangioma, benign neoplasm of cecum

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.